These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 7936353)

  • 1. [Systemic sclerosis after a long-term follow-up].
    Danese C; Zavattaro E; Marcianò F; Sebastiani ML; Perego MA
    Minerva Med; 1994; 85(7-8):359-64. PubMed ID: 7936353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
    Rychlik-Golema W; Mastej K; Adamiec R
    Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis.
    Sulli A; Soldano S; Pizzorni C; Montagna P; Secchi ME; Villaggio B; Seriolo B; Brizzolara R; Cutolo M
    J Rheumatol; 2009 Jun; 36(6):1235-9. PubMed ID: 19369451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
    Dziadzio M; Denton CP; Smith R; Howell K; Blann A; Bowers E; Black CM
    Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated Raynaud's phenomenon--a benign disorder.
    Sheiner NM; Small P
    Ann Allergy; 1987 Feb; 58(2):114-7. PubMed ID: 3492946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostacyclin analogue iloprost influences endothelial cell-associated soluble adhesion molecules and growth factors in patients with systemic sclerosis: a time course study of serum concentrations.
    Rehberger P; Beckheinrich-Mrowka P; Haustein UF; Sticherling M
    Acta Derm Venereol; 2009; 89(3):245-9. PubMed ID: 19479119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Juvenile systemic sclerosis: a follow-up study of eight patients.
    Szamosi S; Maródi L; Czirják L; Ellenes Z; Szücs G
    Ann N Y Acad Sci; 2005 Jun; 1051():229-34. PubMed ID: 16126963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients.
    Dziankowska-Bartkowiak B; Zalewska A; Sysa-Jedrzejowska A
    Med Sci Monit; 2004 May; 10(5):CR202-8. PubMed ID: 15114270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study.
    Pamuk GE; Turgut B; Pamuk ON; Vural O; Demir M; Cakir N
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):297-302. PubMed ID: 17473568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment.
    Kumar N; Griffiths B; Allen J
    J Rheumatol; 2006 Sep; 33(9):1918-9. PubMed ID: 16960964
    [No Abstract]   [Full Text] [Related]  

  • 16. Endothelin-1 and cold provocation in health, primary Raynaud's phenomenon, and progressive systemic sclerosis.
    Dörffler-Melly J; Lüscher TF; Wenk M; Wen S; Bollinger A; Franzeck UK
    Microvasc Res; 1996 Sep; 52(2):193-7. PubMed ID: 8901448
    [No Abstract]   [Full Text] [Related]  

  • 17. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S; Wigley FM
    Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon.
    Marasini B; Casari S; Bestetti A; Maioli C; Cugno M; Zeni S; Turri O; Guagnellini E; Biondi ML
    J Rheumatol; 2000 Nov; 27(11):2621-3. PubMed ID: 11093443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to diagnosis in systemic sclerosis: is sex a factor?
    Hudson M; Thombs B; Baron M;
    Arthritis Rheum; 2009 Feb; 61(2):274-8. PubMed ID: 19177534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.